



VALIDATING DIAGNOSTICS TO  
**COMBAT ANTIMICROBIAL RESISTANCE**  
BY OPTIMISING ANTIBIOTIC USE

 [WWW.VALUE-DX.EU](http://WWW.VALUE-DX.EU)

## VALUE-Dx gets involved in WAAW 2019

World Antibiotic Awareness Week is a campaign that is held in November and was initiated by WHO. It now involves initiatives and organisations all over the world that are committed to tackling antibiotic resistance through raising global awareness on proper handling of antibiotics and sharing good practices. This year, it is held from 18 to 24 November and VALUE-Dx is getting involved! Check the official [VALUE-Dx WAAW page](#) and share our communication materials!



VALUE-Dx gets involved in **World Antibiotic Awareness Week 2019**

[Download the animation](#)

[Download the infographic](#)

---

## WP4 kick-off meeting in Zeist

On 24th and 25th of October 2019, the kick-off meeting for [WP4](#) of VALUE-Dx took place in Zeist, the Netherlands. Representatives from different community care settings, from the industry partners and from other work packages came


together in preparation for the point prevalence audit survey (PPAS) which is planned to take place during the 'high-peak' winter season (January-March 2020) in 21 countries across Europe. The PPAS aims at describing the presentation and management of community-acquired acute respiratory tract infections (CA-ARTI). [Read more](#)



---

## VALUE-Dx at the ERS International Congress 2019

On 28 September to 2 October 2019, the European Respiratory Society ([ERS](#)) organised its annual International Congress of 2019 in Madrid, Spain. A symposium was held on '**Fighting antimicrobial resistance: from prevention to antimicrobial stewardship**' that was chaired by WP6 co-lead Prof. Murat Akova of ESCMID and Dr. Eva Polverino of ERS. Project lead of VALUE-Dx, Prof. Dr. Herman Goossens, gave a compelling talk on '**The new era of diagnostics: will it ever start?**', presenting the evolving market of in vitro diagnostics as the world's largest med-tech sector. [Read more](#)



---

## WP2 first face-to-face meeting in Antwerp

On 27 September 2019, the first [WP2](#) face-to-face meeting took place in Antwerp. With 15 attendees, all partners involved in WP2 were well represented. After some updates on the WP2 division of work and building of the External Advisory Panel, every partner presented their capabilities to successfully carry out their tasks. University of Antwerp described their expertise on the different areas required in this WP, such as biomarker research, next generation sequencing techniques, bioinformatic tools and biobanking activities including the set-up of the Antwerp biobank that is ready to receive samples from [WP4](#). [Read more](#)



---

## VALUE-Dx at the 10th Advanced Course on Diagnostics in Annecy

The [10th Advanced Course on Diagnostics](#) organised by Mérieux Foundation and the London School of Hygiene & Tropical Medicine was held at Annecy, France, from the 15th to the 20th of September. A week-long intensive course that brought together professional participants from across 35 countries, the focus of this course was on the role and the value of diagnostics in global health for antimicrobial resistance control. Prof. Dr. Herman Goossens, Coordinator and Project Leader of VALUE-Dx, gave a talk on **‘Setting the scene for public-private collaborations in diagnostics’** for the session on **‘Role and value of diagnostics in Global Health’**. [Read more](#)

---

## VALUE-Dx Summary October 2019 Update

This summary provides more information on the future work that VALUE-Dx will carry out in the coming years across 20 European countries on community-acquired acute respiratory tract infections (CA-ARTI). This

includes details for the three winter seasons from 2019 to 2022. [Read more](#)

Download the VALUE-Dx Summary October 2019

## UPCOMING EVENTS

- [WP Co-Lead-Face-To-Face & Business Plan meeting, Amsterdam Schiphol - 28-29 November 2019](#)
- [VALUE-Dx General Assembly, Bologna - 9-10 June 2020](#)



Copyright © 2019 VALUE-Dx, All rights reserved.



innovative  
medicines  
initiative



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is:  
[value\\_dx@uantwerpen.be](mailto:value_dx@uantwerpen.be)